Levomethadone Hydrochloride Dne

Levomethadone Hydrochloride, the active ingredient in Levomethadone Hydrochloride Dne, is a synthetic opioid presented as an oral dosage form for oral use. It is employed in the management of opioid dependence and chronic pain in adult patients.

GNH USA supplies Levomethadone Hydrochloride Dne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levomethadone Hydrochloride is used in the opioid pathway to treat dependence and severe pain.

- Opioid dependence: reduces withdrawal symptoms and cravings during detoxification. - Chronic pain: provides analgesia for severe, persistent pain unresponsive to other treatments. - Opioid substitution therapy: serves as a maintenance option to stabilize patients on a controlled opioid regimen.

Levomethadone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Sweating - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Seizures - Severe hypotension - Allergic reactions (anaphylaxis) - Adrenal insufficiency

When prescribing Levomethadone Hydrochloride, clinicians should observe several safety considerations.

- Assess respiratory function: evaluate for asthma, COPD, or sleep‑apnea before initiating therapy. - Monitor sedation: watch for excessive drowsiness or impaired cognition, especially during dose titration. - Avoid concurrent CNS depressants: limit use with benzodiazepines, barbiturates, or alcohol. - Use caution in hepatic impairment: dose adjustments may be required in patients with liver disease. - Use caution in renal impairment: monitor for accumulation in severe kidney dysfunction. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levomethadone Hydrochloride interacts with several drug classes that can alter its safety or effectiveness.

Major Interactions (Avoid): - Concomitant opioids: additive respiratory depression and sedation. - Benzodiazepines or other CNS depressants: heightened risk of profound sedation and respiratory compromise. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - SSRIs or other serotonergic agents: potential for serotonin syndrome.